CD27 and neoplasm: In line with this, ruxolitinib treatment of non-tumour-bearing mice skewed the pattern of NK-cell maturation defined by CD11b and CD27 expression38, 39 (Fig. 5a), and reduced the percentage of NK cells expressing the maturation markers DNAM1 and KLGR1 (Fig. 5b,c).